JB Chemicals & Pharmaceuticals Ltd (JB Pharma) announced its unaudited consolidated financial results for the quarter ended December 31, 2025. The company recorded a revenue of ₹1,065 crore in Q3 FY26, an 11% increase from ₹963 crore in Q3 FY25. Operating EBITDA saw a rise of 13% to ₹305 crore from ₹270 crore in the same period last year. Net Profit increased by 22% to ₹198 crore, up from ₹162 crore in Q3 FY25.

For the nine months of FY26 (9M FY26), JB Pharma reported revenue of ₹3,244 crore, a 9% growth compared to ₹2,969 crore in 9M FY25. Operating EBITDA for 9M FY26 increased by 13% to ₹955 crore from ₹846 crore in the prior year. Profit After Tax for 9M FY26 grew by 18% to ₹608 crore, up from ₹514 crore in 9M FY25.

Mr. Nikhil Chopra, CEO and Wholetime Director, stated that the domestic formulations business outperformed the Indian pharmaceutical market, driven by momentum across key chronic therapies and flagship brands. The international formulations business also showed strong growth in key markets, alongside the continued positive momentum in the CDMO business. The company's focus on cost optimization, favorable product mix, and operational efficiencies led to improved operating margins. JB Pharma remains confident in its ability to deliver profitable growth, with priorities focused on strengthening brand franchises, accelerating chronic therapy growth, scaling CDMO businesses, and building a resilient organization.

The domestic formulations business recorded revenue of ₹620 crore in Q3 FY26, a 10% increase from ₹566 crore in Q3 FY25. The international business revenue grew by 12% to ₹445 crore, with international formulations growing by 20% to ₹306 crore. The CDMO business revenue was nearly flat at ₹117 crore in Q3 FY26, with sales momentum expected to continue in Q4 FY26.